Clinical trials
Hypotension trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Recruiting | 5 |
| Terminated | 5 |
| Unknown status | 4 |
| Not yet recruiting | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 4 |
| University Hospital, Clermont-Ferrand | 4 |
| Theravance Biopharma | 3 |
| University Hospital, Caen | 3 |
| University Hospital, Toulouse | 3 |
| Centre Hospitalier Régional d'Orléans | 2 |
| Hopital Foch | 2 |
| Nantes University Hospital | 2 |
| University Hospital, Montpellier | 2 |
| Azienda Ospedaliera di Lecco | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypotension | 42 |
| Hypertension | 4 |
| Dizziness | 3 |
| Hypotension, Orthostatic | 3 |
| Parkinson Disease | 3 |
| Parkinsonian Disorders | 3 |
| Pure Autonomic Failure | 3 |
| Syncope | 3 |
| Hyperglycemia | 2 |
| Shock | 2 |
Trials
Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.